全文获取类型
收费全文 | 422篇 |
免费 | 36篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 12篇 |
妇产科学 | 9篇 |
基础医学 | 64篇 |
口腔科学 | 3篇 |
临床医学 | 44篇 |
内科学 | 69篇 |
皮肤病学 | 6篇 |
神经病学 | 54篇 |
特种医学 | 8篇 |
外科学 | 46篇 |
综合类 | 1篇 |
预防医学 | 68篇 |
眼科学 | 3篇 |
药学 | 32篇 |
中国医学 | 3篇 |
肿瘤学 | 27篇 |
出版年
2024年 | 2篇 |
2023年 | 16篇 |
2022年 | 29篇 |
2021年 | 46篇 |
2020年 | 28篇 |
2019年 | 39篇 |
2018年 | 37篇 |
2017年 | 17篇 |
2016年 | 21篇 |
2015年 | 23篇 |
2014年 | 16篇 |
2013年 | 32篇 |
2012年 | 25篇 |
2011年 | 32篇 |
2010年 | 11篇 |
2009年 | 17篇 |
2008年 | 13篇 |
2007年 | 22篇 |
2006年 | 12篇 |
2005年 | 7篇 |
2004年 | 4篇 |
2003年 | 3篇 |
2002年 | 6篇 |
排序方式: 共有458条查询结果,搜索用时 218 毫秒
61.
Yan CT Kaushal D Murphy M Zhang Y Datta A Chen C Monroe B Mostoslavsky G Coakley K Gao Y Mills KD Fazeli AP Tepsuporn S Hall G Mulligan R Fox E Bronson R De Girolami U Lee C Alt FW 《Proceedings of the National Academy of Sciences of the United States of America》2006,103(19):7378-7383
Inactivation of the XRCC4 nonhomologous end-joining factor in the mouse germ line leads to embryonic lethality, in association with apoptosis of newly generated, postmitotic neurons. We now show that conditional inactivation of the XRCC4 in nestin-expressing neuronal progenitor cells, although leading to no obvious phenotype in a WT background, leads to early onset of neuronally differentiated medulloblastomas (MBs) in a p53-deficient background. A substantial proportion of the XRCC4/p53-deficient MBs have high-level N-myc gene amplification, often intrachromosomally in the context of complex translocations or other alterations of chromosome 12, on which N-myc resides, or extrachromosomally within double minutes. In addition, most XRCC4/p53-deficient MBs harbor clonal translocations of chromosome 13, which frequently involve chromosome 6 as a partner. One copy of the patched gene (Ptc), which lies on chromosome 13, was deleted in all tested XRCC4/p53-deficient MBs in the context of translocations or interstitial deletions. In addition, Cyclin D2, a chromosome 6 gene, was amplified in a subset of tumors. Notably, amplification of Myc-family or Cyclin D2 genes and deletion of Ptc also have been observed in human MBs. We therefore conclude that, in neuronal cells of mice, the nonhomologous end-joining pathway plays a critical role in suppressing genomic instability that, in a p53-deficient background, routinely contributes to genesis of MBs with recurrent chromosomal alterations. 相似文献
62.
63.
Brianna R. Altman M.N. Mian M. Slavin M. Earleywine 《Journal of psychoactive drugs》2013,45(5):405-412
ABSTRACTUp to 35% of adults in the United States suffer from sleep disturbances, which covary with a host of negative mental and physical health outcomes. Previous research suggests that cannabis’ sedative effects may be associated with improved sleep. The present study examined the self-reported effect of cannabis use on individual’s sleep-related problems. Participants included 311 individuals recruited online, who reported both sleep-related problems and cannabis use. Analyses revealed that participants expected cannabis to decrease the incidence of sleep-related problems, including allowing participants to have an earlier bedtime, to fall asleep more quickly, and to have a longer night’s sleep. Moreover, expectancies about the influence of cannabis on sleep negatively covaried with cannabis-related problems. These findings suggest that individuals believe using cannabis might positively influence their sleep quality and believing so may be protective against cannabis problems. Randomized control trials of cannabis for insomnia appear justified. 相似文献
64.
Insulin resistance and type 2 diabetes have been treated with the PPARγ agonists thiazolidinediones, or TZDs, since the 1990s. One mechanism by which these drugs may work is through PPARγ-mediated upregulation of adiponectin, an endogenous adipokine that has been shown to increase insulin sensitivity. Interestingly, α- and γ-tocopherol, two vitamin E vitamers, have structural similarities to the TZDs and have also been linked to enhanced insulin sensitivity. A recent study identified a novel function of α- and γ-tocopherol in 3T3-L1 preadipocytes: upregulation of an endogenous ligand involved in activating PPARγ. This study also found that tocopherols dramatically enhanced adiponectin expression and that this effect was mediated through a PPARγ-dependent process. These findings illustrate a possible mechanistic link between vitamin E and insulin sensitivity. 相似文献
65.
66.
Banwait R O'Regan K Campigotto F Harris B Yarar D Bagshaw M Leleu X Leduc R Ramaiya N Weller E Ghobrial IM 《American journal of hematology》2011,86(7):567-572
Disease assessment in WM is dependent on the quantification of the IgM monoclonal protein and percent involvement of the bone marrow. There is a need for imaging studies that objectively measure tumor load in these patients. In this study, we sought to examine the role of combined FDG-PET/CT imaging in the detection of tumor load and in the assessment of response to therapy. Thirty-five patients were enrolled on a prospective study using bortezomib and rituximab therapy and were included in this study because they completed a pre- and post-treatment FDG-PET/CT imaging at one facility (12 newly diagnosed and 23 relapsed/refractory). The use of combined FDG-PET/CT imaging showed positive findings in 83% of patients with WM, unlike prior studies using conventional imaging that indicate that only 20% of patients have lymphadenopathy or hepatosplenomegaly. Moreover, 43% of patients had abnormal bone marrow uptake on FDG-PET imaging that can potentially help in the assessment of their tumor load, especially with heterogenous sampling of the bone marrow. There was no statistical correlation between EORTC response criteria for FDG-PET/CT and response by monoclonal protein. This is the first study to examine the role of FDG-PET/CT imaging in WM. Future studies should examine the role of FDG-PET/CT in conjunction with monoclonal protein response in the assessment of progression-free survival in patients with WM. 相似文献
67.
Ghobrial IM Munshi NC Harris BN Shi P Porter NM Schlossman RL Laubach JP Anderson KC Desaiah D Myrand SP Wooldridge JE Richardson PG Abonour R 《American journal of hematology》2011,86(7):573-578
The purpose of this study was to assess the safety and identify the recommended doses of enzastaurin and bortezomib in combination for future Phase II studies in patients with relapsed or refractory multiple myeloma. Three dose levels (DLs) of oral enzastaurin and intravenous bortezomib were used according to a conventional "3 + 3" design. A loading dose of enzastaurin (250 mg twice/day [BID]) on Day 1 was followed by enzastaurin 125 mg BID for 1 week, after which bortezomib was added (Cycle 1, 28 days, 1.0 mg/m(2) : Days 8, 11, 15, and 18; seven subsequent 21-day cycles, 1.3 mg/m(2) : Days 1, 4, 8, and 11). Twenty-three patients received treatment; all patients received prior systemic therapy. Most patients received ≥3 regimens; 17 patients were bortezomib-refractory. A median of four treatment cycles (range 1-24) was completed. No dose-limiting toxicities were observed; thus, DL 3 was the recommended Phase II dose. The most common drug-related Grade 3/4 toxicities were thrombocytopenia (n = 6) and anemia (n = 2). No patients died on therapy. One patient (DL 1) achieved a very good partial response; three patients (DLs 2 and 3), a partial response; nine patients, stable disease; and four patients, progressive disease. The recommended Phase II doses in patients with relapsed or refractory multiple myeloma are as follows: enzastaurin loading dose of 375 mg three times/day on Day 1 followed by 250 mg BID, with bortezomib 1.3 mg/m(2) on Days 1, 4, 8, and 11 of a 21-day cycle. The combination was well-tolerated and demonstrated some antimyeloma activity. 相似文献
68.
69.